Warner Chilcott Commences Tender Offer for its 8.75% Senior Subordinated Notes due 2015

ARDEE, Ireland, Dec. 15  /PRNewswire-FirstCall/ -- Warner Chilcott plc (NASDAQ:WCRX) today announced that its subsidiary Warner Chilcott Corporation (the "Company") has commenced a cash tender offer, on the terms and subject to the conditions set forth in the Company's Offer to Purchase and Consent Solicitation Statement dated December 15, 2009 (the "Offer to Purchase"), for any and all of its outstanding 8.75% senior subordinated notes due 2015 (the "Notes").

The Company is also soliciting consents to certain proposed amendments to the indenture governing the Notes to, among other things, eliminate substantially all of the restrictive covenants and certain events of default and eliminate or modify related provisions contained in the indenture.

The Offer to Purchase more fully sets forth the terms of the tender offer and consent solicitation.

The Notes and other information relating to the tender offer are listed in the table below:

            Title    Principal     Tender
   CUSIP/     of      Amount       Offer          Consent       Total
  ISIN No. Security Outstanding Consideration(1) Payment(2) Consideration(1)
  -------- -------- ----------- ---------------- ---------- ----------------
            8.75%
            Senior
            Notes
            due
  93443MAC5 2015   $380,000,000    $1017.50        $30.00      $1047.50



  (1)  Per $1,000 principal amount of Notes and excluding accrued and
       unpaid interest, which will be paid in addition to the Total
       Consideration or Tender Offer Consideration, as applicable.
  (2)  Per $1,000 principal amount of Notes tendered prior to the
       Consent Date (as defined below).



Holders who validly tender their Notes prior to 11:59 p.m., New York City time, on Tuesday, December 29, 2009, (the "Consent Date") shall receive total consideration of $1047.50 per $1,000 principal amount of Notes tendered, which includes a consent payment of $30.00 per $1,000 principal amount of Notes. Holders must validly tender and not validly withdraw their Notes at or prior to the Consent Date in order to be eligible to receive the total consideration (including the consent payment). Holders tendering their Notes after the Consent Date will receive only the tender offer consideration of $1017.50 per $1,000 principal amount of Notes tendered.

The Company will pay accrued and unpaid interest on all Notes tendered and accepted for payment in the tender offer from the last interest payment date to, but not including, the date on which the Notes are purchased.

The tender offer is scheduled to expire at 11:59 p.m., New York City time, on January 14, 2010, unless extended or earlier terminated by the Company (the "Expiration Date"). Any Notes tendered on or prior to the Consent Date that are not validly withdrawn on or prior to the Consent Date may not be withdrawn thereafter except as required by law.  Tenders of Notes after the Consent Date may not be validly withdrawn except as required by law.

Holders may not tender their Notes without delivering their consents to the proposed amendments to the indenture and may not deliver their consents without tendering their Notes pursuant to the tender offer. The proposed amendments will not become effective, however, until after a majority in aggregate principal amount of the outstanding Notes, whose holders have delivered consents to the proposed amendments, have been accepted for payment.

The Company has reserved the right to (and expects to) accept for purchase Notes tendered prior to the Consent Date on a date prior to the Expiration Date (the "Early Settlement Date," expected to be December 30, 2009). On the Early Settlement Date, the Company will also pay accrued and unpaid interest from the last interest payment date for the Notes up to, but not including, the Early Settlement Date on the Notes accepted for purchase.

The Company's obligation to accept for purchase and to pay for Notes validly tendered and not withdrawn pursuant to the tender offer and the consent solicitation is subject to the satisfaction or waiver, in the Company's discretion, of certain conditions, which are more fully described in the Offer to Purchase, including, among other things, receipt of the requisite number of consents to the proposed amendments to the indenture and the Company's consummation of an amendment to its senior secured facilities to provide for an additional $350.0 million Term B loan facility on or prior to the Early Settlement Date.  The Company expects to fund the total consideration with proceeds from the new $350.0 million Term B loan facility together with cash on hand.

The Company has retained Banc of America Securities LLC to serve as the dealer manager and solicitation agent for the tender offer and consent solicitation. Questions regarding the tender offer and consent solicitation may be directed to [phone] (collect) or [phone] (toll-free). Requests for documents may be directed to Global Bondholder Services, Inc., the information agent for the tender offer, at [phone] (banks and brokers) or [phone] (toll-free).

This press release is for informational purposes only and is not an offer to purchase, a solicitation of an offer to purchase or a solicitation of consent with respect to any securities. The tender offer and consent solicitation is being made solely pursuant to the Offer to Purchase and the related Letter of Transmittal and Consent, which set forth the complete terms of the tender offer and consent solicitation.

Warner Chilcott

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the gastroenterology, women's healthcare, dermatology and urology segments of the U.S. and Western European pharmaceuticals markets. Warner Chilcott is a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of its products. WCRX-G.

  Read more on http://www.wcrx.com/.

  Forward Looking Statements:


This press release contains forward-looking statements, including statements concerning our operations, our economic performance and financial condition, and our business plans and growth strategy and product development efforts. These statements constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The words "may," "might," "will," "should," "estimate," "project," "plan," "anticipate," "expect," "intend," "outlook," "believe" and other similar expressions are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. These forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. The following represent some, but not necessarily all, of the factors that could cause actual results to differ from historical results or those anticipated or predicted by our forward-looking statements: our substantial indebtedness; competitive factors in the industry in which we operate (including the approval and introduction of generic or branded products that compete with our products); our ability to protect our intellectual property; a delay in qualifying our manufacturing facilities to produce our products or production or regulatory problems affecting either third party manufacturers upon whom we may rely for some of our products or our own manufacturing facilities; pricing pressures from reimbursement policies of private managed care organizations and other third party payors, government sponsored health systems, the continued consolidation of the distribution network through which we sell our products, including wholesale drug distributors and the growth of large retail drug store chains; the loss of key senior management or scientific staff; adverse outcomes in our outstanding litigation or an increase in the number of litigation matters to which we are subject; government regulation affecting the development, manufacture, marketing and sale of pharmaceutical products, including our ability and the ability of companies with whom we do business to obtain necessary regulatory approvals; our ability to manage the growth of our business by successfully identifying, developing, acquiring or licensing new products at favorable prices and marketing such new products; our ability to obtain regulatory approval and customer acceptance of new products, and continued customer acceptance of our existing products; changes in tax laws or interpretations that could increase our consolidated tax liabilities; the other risks identified in our periodic filings including our Annual Report on Form 10-K for the year ended December 31, 2008, as amended, and our Current Report on Form 8-K filed on November 2, 2009; and other risks detailed from time-to-time in our public filings, financial statements and other investor communications.

We caution you that the foregoing list of important factors is not exclusive. In addition, in light of these risks and uncertainties, the matters referred to in our forward-looking statements may not occur. We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law. 

DATASOURCE: Warner Chilcott plc



CONTACT:  Rochelle Fuhrmann, Investor Relations, [phone],





Web Site:  http://www.wcrx.com/ 

Copyright